Pfizer to Acquire Therachon for Up to $810M Expanding Rare Disease Pipeline

Pfizer to Acquire Therachon for Up to $810M, Expanding Rare Disease Pipeline

Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a pipeline to be led by a clinical-phase candidate for the most common form of short-limbed dwarfism. Therachon’s TA-46 is a soluble recombinant human fibroblast growth factor […]

More From BioPortfolio on "Pfizer to Acquire Therachon for Up to $810M, Expanding Rare Disease Pipeline"